



Grant Number: 5U01CA033193-30 REVISED

Principal Investigator(s):

Kurt Straif

Project Title: Evaluation of Carcinogenic Risks to Humans

Olaf Kelm
INTERNATIONAL AGENCY-RES CANCER

150 COURS ALBERT THOMAS
F-69372 LYON CEDEX 08, FRANCE,
FRANCE

Award e-mailed to: igo@iarc.fr

Budget Period: 09/01/2011 – 08/31/2012

Project Period: 09/01/1985 – 08/31/2015

Dear Business Official:

The National Institutes of Health hereby revises this award (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as “The project described was supported by Grant Number U01CA033193 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients are required to comply with the NIH Public Access Policy. This includes submission to PubMed Central (PMC), upon acceptance for publication, an electronic version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

Award recipients must promote objectivity in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including the Investigator's spouse and dependent children. Awardees must have a written administrative process to identify and manage financial conflict of interest and must inform Investigators of the conflict of interest policy and of the Investigators' responsibilities. Prior to expenditure of these awarded funds, the Awardee must report to the NIH Awarding Component the existence of a conflicting interest and within 60 days of any new conflicting interests identified after the initial report. Awardees must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also apply to

subgrantees, contractors, or collaborators engaged by the Awardee under this award. The NIH website <http://grants.nih.gov/grants/policy/coi/index.htm> provides additional information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Joy Kearse
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5U01CA033193-30 REVISED

Award Calculation (U.S. Dollars)

Salaries and Wages	\$401,375
Fringe Benefits	\$133,790
Personnel Costs (Subtotal)	\$535,165
Consultant Services	\$24,485
Travel Costs	\$2,166
Other Costs	\$156,186

Federal Direct Costs	\$718,002
Federal F&A Costs	\$115,598
Approved Budget	\$833,600
Federal Share	\$833,600
Less Unobligated Balance	\$516
TOTAL FEDERAL AWARD AMOUNT	\$833,084

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$0

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
30	(b)(5)	
31		
32		
33		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number: 93.393
 EIN: 1900210016A1
 Document Number: UCA033193G
 Fiscal Year: 2011

IC	CAN	2011	2012	2013	2014
CA	8479565	\$833,084	(b)(5)		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A3CE / OC: 414P / Processed: KEARSEJ 09/01/2011

SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-30 REVISED

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5U01CA033193-30 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award may be subject to the Transparency Act subaward and executive compensation reporting requirements of 2 CFR Part 170. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Treatment of Program Income: Additional Costs

SECTION IV – CA Special Terms and Conditions – 5U01CA033193-30 REVISED

INFORMATION: In accordance with the National Cancer Institute's implementation of the NIH Fiscal Year 2011 funding policy, this award has been funded at 94.17% of the level previously committed for this budget period. Support recommended for future years has been adjusted to reflect a 2% cost of living adjustment.

THE FOLLOWING TERMS FROM THE PREVIOUS NOTICE OF GRANT AWARD ISSUED ON 9/1/11 ALSO APPLY TO THIS AWARD:

REQUIREMENT: This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award below, which are hereby incorporated by reference as special terms and conditions of this award.

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

Collaborative Terms of Award

Nature of Collaboration with NCI Staff

NCI has certain responsibilities in terms of this cooperative agreement which involve assistance, information support, and scientific collaboration.

1. Scientific Resource

Since the monographs on each chemical which appear in the columns published by IARC are fundamentally an international information resource and data bank on carcinogenesis and evaluation of qualitative risk of chemicals to human, NCI, in an assistance and cooperative role, provides information and data which assist IARC staff in the preparation of certain sections of the final monograph (Sections 1.1 to 2.3). Sections 3.1 to 4.3 are developed by the Working Groups which consist of international scientists who review all these documents at the time of the

meetings (3 per year) in Lyon, France. The National Cancer Institute, through arrangements with a contractor will provide such assistance.

2. Planning for Meetings of the Working Group

The IARC project is one of international support with NCI being the USA supporter for the monograph and the Information Bulletins on the Survey of Chemicals Being Tested for Carcinogenicity. This bulletin is a listing of chemicals being tested in laboratories throughout the world. Under the Cooperative Agreement, NCI:

- a. Makes suggestions to IARC on types of chemicals that should be evaluated at the three planned working group meetings per held in Lyon, France.
- b. Makes suggestions and gives assistance to IARC as to USA resource people who should attend and participate in Working Group meetings. Personnel from regulatory agencies and trade associations should attend as observers.

3. Program Involvement in Relation to Input from NCI

Under the section on scientific resources, reference was made to NCI input as to data on production, occurrence, analysis, and use of chemicals. NCI, also provides information relevant to carcinogenicity on chemicals tested in U.S. laboratories. These data are then incorporated in the Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity.

In discussing certain phases of work that involve assistance and collaboration on the part of NCI with IARC, reference was made to the essentiality of effective liaison and support. Participation by the NCI Program Director in the working group meetings in Lyon, France could be either as an observer or as a representative of NCI or as a full member of the working group in his personal capacity as a scientist.

4. Reporting Requirements

NCI wishes to continue a semi-annual reporting requirement with scheduling or due dates for reports worked out by mutual agreement between NCI staff and the IARC principal investigators. The volumes of monographs, supplements and survey bulletins are actually exhibits of achievements and accomplishment. Consequently, the semi-annual reports should dwell on planning, participation, selection of chemicals, problems of interfacing and cooperation and logistical matters. In addition, an annual report to be included in the required continuation applications should reflect that the project continues to conform to the purposes, objectives and conditions of the award and has substantial programmatic involvement by NCI with the performer of the project.

5. Publication and Distribution

One of the significant features of the IARC project in development of this international authoritative reference source is the publication and distribution, on a world-wide basis, of these volumes, including the supplements to the volumes listing Chemicals and Industrial Processes Associated with Cancer in Humans, as well as the Survey Bulletins.

The National Cancer Institute will receive approximately 400 copies of each volume published. The NCI distributes these copies to NCI staff, representatives of other agencies interested in environmental and occupational carcinogenesis, selected university scientist engaged in carcinogenesis research, public health organizations and medical libraries. Therefore, many organizations and scientists in the USA and abroad benefit from this program, which is partially supported by the National Cancer Institute.

The following administrative terms also apply:

INFORMATION: This award utilizes as an offset the unobligated balance from the 28- year financial status report in the amount of \$516.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These

individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Joy Kearse
Email: kearsej@mail.nih.gov **Phone:** 301-631-3002 **Fax:** 301-451-5391

Program Official: Donald G. Blair
Email: db471b@nih.gov **Phone:** 301-496-7028 **Fax:** 301-402-1037

SPREADSHEET SUMMARY

GRANT NUMBER: 5U01CA033193-30 REVISED

INSTITUTION: INTERNATIONAL AGENCY FOR RES ON CANCER

<i>Budget</i>	<i>Year 30</i>	<i>Year 31</i>	<i>Year 32</i>	<i>Year 33</i>
Salaries and Wages	\$401,375	(b)(5)		
Fringe Benefits	\$133,790			
Personnel Costs (Subtotal)	\$535,165			
Consultant Services	\$24,485			
Travel Costs	\$2,166			
Other Costs	\$156,186			
TOTAL FEDERAL DC	\$718,002			
TOTAL FEDERAL F&A	\$115,598			
TOTAL COST	\$833,084			

<i>Facilities and Administrative Costs</i>	<i>Year 30</i>	<i>Year 31</i>	<i>Year 32</i>	<i>Year 33</i>
F&A Cost Rate 1	16.1%	(b)(5)		
F&A Cost Base 1	\$718,002			
F&A Costs 1	\$115,598			

Progress Report Scanning Cover Sheet

5U01CA033193-30

PI Name: **STRAIF, KURT**
Org: **INTERNATIONAL AGENCY FOR RES ON
CANCER**
Start Date: **09/01/2011**
Snap: **N/A (NEEDS TO BE BOOKMARKED)**
Appl ID: **8136330**
Rec'd
Date: **07/07/2011**

Department of Health and Human Services
Public Health Services

Review Group ZCA1RPRB7J1	Type 5	Activity U01	Grant Number 2U01CA033193-29 REV. 30
------------------------------------	------------------	------------------------	--

Grant Progress Report

Total Project Period	
From: 09/01/1985	Through: 08/31/2015
Requested Budget Period	
From: 09/01/2011	Through: 08/31/2012

1. TITLE OF PROJECT
Evaluation of Carcinogenic Risks to Humans

2a. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR
(Name and address, street, city, state, zip code)
Kurt Straif
IARC Monographs Section
International Agency for Research on Cancer
150, Cours Albert Thomas
F-69372 Lyon cedex 08, France

2b. E-MAIL ADDRESS
straif@iarc.fr

2c. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT
IARC Monographs Section

2d. MAJOR SUBDIVISION
IARC Monographs Section

2e. Tel: **33-4-72.73.85.07** Fax: **33-4-72.73.83.19**

3a. APPLICANT ORGANIZATION
(Name and address, street, city, state, zip code)
International Agency for Research on Cancer
150, Cours Albert Thomas
F-69372 Lyon cedex 08, France

3b. Tel: **33-4-72.73.84.85** Fax: **33-4-72.73.85.75**

3c. DUNS: **279551881**

4. ENTITY IDENTIFICATION NUMBER **JUL 07 2011**
1900210016A1

6. HUMAN SUBJECTS No Yes

6a. Research Exempt No Yes

If Exempt ("Yes" in 6a):
Exemption No.

If Not Exempt ("No" in 6a):
IRB approval date

6b. Federal Wide Assurance No. **00005058**

6c. NIH-Defined Phase III Clinical Trial No Yes

5. NAME, TITLE AND ADDRESS OF ADMINISTRATIVE OFFICIAL
Olaf Kelm, External Relations Officer, International Agency for Research on Cancer, 150 Cours Albert Thomas, F-69372 Lyon cedex 08, France

Tel: **33-4-72.73.84.94** Fax: **33-4-72.73.85.64**

E-MAIL: **igo@iarc.fr**

7. VERTEBRATE ANIMALS No Yes

7a. If "Yes," IACUC approval Date

7b. Animal Welfare Assurance No.

10. PROJECT/PERFORMANCE SITE(S)

Organizational Name: **Applicant**

DUNS:

8. COSTS REQUESTED FOR NEXT BUDGET PERIOD

8a. DIRECT \$**762,415** 8b. TOTAL \$**885,164**

Street 1:

Street 2:

9. INVENTIONS AND PATENTS No Yes

If "Yes," Previously Reported Not Previously Reported

City: County:

State: Province:


Country: Zip/Postal Code:

Congressional Districts:

11. NAME AND TITLE OF OFFICIAL SIGNING FOR APPLICANT ORGANIZATION (Item 13)
Christopher P. Wild, Director

TEL: **33-4-72.73.85.77** FAX: **33-4-72.73.85.64** E-MAIL: **director@iarc.fr**

12. Corrections to Page 1 Face Page

13. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.	SIGNATURE OF OFFICIAL NAMED IN 11. (In ink) 	DATE 30/06/11
--	--	-------------------------

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

DETAILED BUDGET FOR NEXT BUDGET PERIOD – DIRECT COSTS ONLY	FROM 09/01/2011	THROUGH 08/31/2012	GRANT NUMBER 2U01CA033193-29 REV.
---	---------------------------	------------------------------	---

List PERSONNEL (Applicant organization only)

Use Cal, Acad, or Summer to Enter Months Devoted to Project

Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summer Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
STRAIF, K.	PD/PI	(b)(4), (b)(6)			0	0	0
EL-GHISSASSI, F.	Scientist				88,541	29,513	118,054
GALICHET, L.	Scientist				78,672	26,224	104,896
BENBRAHIM-TALLAA, L.	Scientist				90,440	30,147	120,587
BOUVARD, V.	Scientist				83,732	27,911	111,643
EGRAZ, S.	Archivist				60,656	20,218	80,874
RUSSELL, D. * (see note 1 on page 3)	Typist				24,161	8,053	32,214
SUBTOTALS →					426,202	142,066	568,268

CONSULTANT COSTS Preparation of Exposure Data sections (see page 3)	26,000
--	--------

EQUIPMENT (Itemize)	
---------------------	--

SUPPLIES (Itemize by category)	
--------------------------------	--

TRAVEL One trip of PI to USA for a scientific meeting and to consult with NCI program officials	2,300
--	-------

INPATIENT CARE COSTS	
----------------------	--

OUTPATIENT CARE COSTS	
-----------------------	--

ALTERATIONS AND RENOVATIONS (Itemize by category)	
---	--

OTHER EXPENSES (Itemize by category) See page 3	165,847
--	---------

SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD	\$ 762,415
---	-------------------

CONSORTIUM/CONTRACTUAL COSTS	DIRECT COSTS	
------------------------------	--------------	--

CONSORTIUM/CONTRACTUAL COSTS	FACILITIES AND ADMINISTRATIVE COSTS	
------------------------------	-------------------------------------	--

TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (Item 8a, Face Page)	\$ 762,415
---	-------------------

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

BUDGET JUSTIFICATION

GRANT NUMBER
2U01CA033193-29 REV.

Provide a detailed budget justification for those line items and amounts that represent a significant change from that previously recommended. Use continuation pages if necessary.

CONSULTANT:

Preparation of Exposure Data sections will be completed through two agreements for performance of work (one per Monographs Volume for \$13,000 each) that will be concluded between the IARC and one or two experts of its choosing.

OTHER:

- Working group Feb-12 Volume 104 (\$75,000 X 1)	\$ 75,000
- Working group Jun-12 Volume 105 (\$75,000 X 1)	\$ 75,000
- Printing of Monographs Volume (\$15,000 X 1)	\$ 15,000
- Books, journals and reproduction costs	\$ 847

	\$165,847

Note 1 to detailed budget. Only (b)(4) % of D. Russell's salary is anticipated to be charged to the grant.

CURRENT BUDGET PERIOD	FROM 09/01/2010	THROUGH 08/31/2011
-----------------------	--------------------	-----------------------

Explain any estimated unobligated balance (including prior year carryover) that is greater than 25% of the current year's total budget.

	Total estimated expenditure -----	Estimated unobligated balance -----
DIRECT COSTS	\$740,209	\$0
INDIRECT COSTS	\$118,680	\$0

TOTAL COSTS	\$858,889	\$0

**For New and Renewal Applications (PHS 398) – DO NOT SUBMIT UNLESS REQUESTED
For Non-competing Progress Reports (PHS 2590) – Submit only Active Support for Key Personnel**

PHS 398/2590 OTHER SUPPORT

Provide active support for all key personnel. **Other Support includes all financial resources, whether Federal, non-Federal, commercial or institutional, available in direct support of an individual's research endeavors, including but not limited to research grants, cooperative agreements, contracts, and/or institutional awards.** Training awards, prizes, or gifts do not need to be included.

There is no "form page" for other support. Information on other support should be provided in the *format* shown below, using continuation pages as necessary. **Include the principal investigator's name at the top and number consecutively with the rest of the application.** The sample below is intended to provide guidance regarding the type and extent of information requested.

For instructions and information pertaining to the use of and policy for other support, see Other Support in the PHS 398 Part III, Policies, Assurances, Definitions, and Other Information.

Note effort devoted to projects must now be measured using person months. Indicate calendar, academic, and/or summer months associated with each project.

Format

NAME OF INDIVIDUAL

ACTIVE/PENDING

Project Number (Principal Investigator) Source Title of Project (or Subproject)	Dates of Approved/Proposed Project Annual Direct Costs	Person Months (Cal/Academic/ Summer)
The major goals of this project are...		

OVERLAP (summarized for each individual)

BAAN, R.

ACTIVE

(b)(4), (b)(6) (Baan)

1/1/2010 – 12/31/2010 (b)(4), (b)(6) calendar

(b)(4), (b)(6)

53,100 euros D.C. (\$75,645)

IARC Monographs Programme 2010

The major goals of this project are to support, in part, a third volume of IARC Monographs each year.

(b)(4), (b)(6) (Baan)

1/1/2011 – 12/31/2011 (b) calendar

(b)(4), (b)(6)

53,100 euros D.C. (\$75,645)

IARC Monographs Programme 2011

The major goals of this project are to support, in part, a third volume of IARC Monographs each year.

PENDING

None.

OVERLAP

None.

STRAIF, K.

BENBRAHIM-TALLAA, L.

BOUVARD, V.

EL-GHISSASSI, F.

GALICHET, L.

GROSSE, Y.

GUHA, N.

LAUBY-SECRETAN, B.

There are no other active or pending sources of support for the key scientists on the IARC Monographs project.

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

PROGRESS REPORT SUMMARY	GRANT NUMBER 2U01CA033193-29 REV.	
	PERIOD COVERED BY THIS REPORT	
PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR STRAIF, Kurt	FROM 1 September 2010	THROUGH 31 August 2011
APPLICANT ORGANIZATION International Agency for Research on Cancer		
TITLE OF PROJECT (Repeat title shown in Item 1 on first page) Evaluation of Carcinogenic Risks to Humans		
A. Human Subjects (Complete Item 6 on the Face Page)		
Involvement of Human Subjects	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
B. Vertebrate Animals (Complete Item 7 on the Face Page)		
Use of Vertebrate Animals	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
C. Select Agent Research	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
D. Multiple PD/PI Leadership Plan	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
E. Human Embryonic Stem Cell Line(s) Used	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change

SEE PHS 2590 INSTRUCTIONS.

WOMEN AND MINORITY INCLUSION: See PHS 398 Instructions. Use Inclusion Enrollment Report Format Page and, if necessary, Targeted/Planned Enrollment Format Page.

A. Specific Aims

The aim of the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, physical agents, biological agents, occupational exposures, and lifestyle factors. International, interdisciplinary Working Groups of expert scientists develop the critical reviews and evaluations, which are published in the IARC Monographs series.

B. Studies and Results

IARC convened meetings to develop two new volumes of Monographs (Vol. 101 and 102) and is preparing for three meetings (Volumes 103-105) that will be convened during the next budget period (1 Sept 2011 to 31 Aug 2012). IARC also finished publishing the backlog of pre-Volume 100 monographs and published Volume 100A (Pharmaceuticals) and Volume 100B (Biological Agents) on-line. Volumes 100C-F are currently being checked and will be published on-line before the end of 2011. Volumes 100A-F are updating the Monographs on the more than 100 agents that had been classified as carcinogenic to humans (Group 1) in Volumes 1-99.

Volume 101: Some Chemicals in Industrial and Consumer Products, Food Contaminants and Flavourings, and Water Chlorination By-Products, 15-22 February 2011

The WG evaluated 18 chemicals present in industrial and consumer products or food—as natural constituents, contaminants, or flavourings—or occurring as water chlorination by products. For all 18 agents (2-nitrotoluene, 1-amino-2,4-dibromoanthraquinone, anthraquinone, cumene, di(2-ethylhexyl)phthalate, diethanolamine, coconut oil, diethanolamine condensate, benzophenone, 2,4-hexadienal, methyleugenol, methyl isobutyl ketone, 1,3-dichloro-2-propanol, 3-monochloro-1,2--propanediol, 2-methylimidazole,

4-methylimidazole, bromochloroacetic acid, dibromoacetic acid, dibromoacetonitrile), the WG concluded that there was "sufficient evidence of carcinogenicity in experimental animals", leading to an overall evaluation—in the absence of adequate epidemiological information—of "possibly carcinogenic to humans" (Group 2B). The only exception was 2-nitrotoluene which was up-graded to Group 2A based on mechanistic considerations. The relevance to humans of the tumours reported in these studies was discussed with regard to mechanisms of carcinogenesis—eg, genotoxicity or other effects, such as peroxisome proliferation and PPARalpha activation, alpha2u-globulin nephropathy and metabolism via CYP2F enzymes.

Volume 102: Non-Ionizing Radiation, Part II: Radiofrequency Electromagnetic Fields [includes mobile telephones], 24-31 May 2011

Human exposures to RF-EMF (frequency range 30 kHz–300 GHz) can occur from use of personal devices (eg, mobile telephones, cordless phones, Bluetooth, and amateur radios), from occupational sources (eg, induction heaters, and high-powered pulsed radars), and from environmental sources such as mobile-phone base stations, broadcast antennas, and medical applications. The WG concluded that there is "limited evidence in humans" for the carcinogenicity of RF-EMF, based on positive associations between glioma and acoustic neuroma and exposure to RF-EMF from wireless phones and classified RF-EMF as "possibly carcinogenic to humans" (Group 2B).

The production process was further improved. Starting with the documentation of the Monographs production workflow, from topic identification to publication, areas for improvements and streamlining were identified, resulting in the integration of XML-based editorial software coupled with state-of-the-art XML-based single source publishing technologies. This had a major impact on clearing the backlog and bringing the programme back on track.

IARC is making the full text of all *Monographs* freely available on the *Monographs* programme website (<http://monographs.iarc.fr/>). All volumes published since Volumes 48 (1990) and Supplement 7 are now available, as well as the summary sections 5 of the Volumes 1 – 47.

D. Plans. During the next budget period, IARC will convene three more expert Working Groups and two scientific workshops to develop the Vol. 100 appendices as follows:

Vol. 103: Bitumen and bitumen fumes, and some heterocyclic polycyclic aromatic hydrocarbons (11-18 October 2011)

Vol. 104: Polyomaviruses (SV40, BK, JC, and Merkel cell viruses) and malaria (7-14 February 2012)

Vol. 105: Diesel and gasoline engine exhausts and some nitroarenes (5-12 June 2012)

Vol 100 appendices: *Tumour Site Concordance between Humans and Animals* and *Mechanisms Involved in Human Carcinogenesis*. These will help to increase understanding of the correspondence across species, facilitate joint consideration of agents that act through similar mechanisms, identify biomarkers that could be influential in future studies, identify susceptible populations and developmental stages and promote research that will lead to more confident evaluations.

IARC will also focus attention on checking the Volumes 100C-F as well as 101-103 and preparing them for publication. Further streamlining of the workflow will include the testing of the new IARC online publications system that will be completed with Volume 103. IARC will continue making the full text of all *Monographs* freely available on the *Monographs* programme website (<http://monographs.iarc.fr/>). Volumes 1 - 47 will be added as soon as they are scanned and formatted.

Further improvements of the dissemination will include: Completion of a relational database of monograph results (based on MySQL), which will be fully searchable, enable complex queries, and will link to other IARC databases (IARC Blue Books, Globocan, etc); development of the ePub format of the monographs for delivery to e-book readers and tablets.

E. Publications

- Baan R, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Islami F, Galichet L, Straif K, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of radiofrequency electromagnetic fields. *Lancet Oncol.*, doi:10.1016/S1470-2045(11)70147-4
- Cogliano VJ, Baan R, Straif K; IARC Monographs programme staff. Updating IARC's carcinogenicity assessment of benzene. *Am. J. Ind. Med.* 2011, 54, 165-167
- Grosse Y, Baan R, Secretan-Lauby B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Islami f, Galichet L, Straif K, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of some chemicals in industrial and consumer products, some food contaminants and additives, and water chlorination by-products. *Lancet Oncol.* 2011; 12: 328-329
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 92, Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and some Related Exposures. IARC, Lyon, France, 2010.
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 93, Carbon Black, Titanium Dioxide and Talc. IARC, Lyon, 2010
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 94, Ingested Nitrate and Nitrite and Cyanobacterial Peptide Toxins. IARC, Lyon, France, 2010
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 95, Household Use of Solid Fuels and High-temperature Frying. IARC, Lyon, France, 2010
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 96, Alcohol Consumption and Ethyl Carbamate. IARC, Lyon, 2010
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 98, Painting, Firefighting and Shiftwork. IARC, Lyon, 2010
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 99, Some Aromatic Amines, Organic Dyes, and Related Exposures. IARC, Lyon, 2010
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100A, A Review of Human Carcinogens: Pharmaceuticals. IARC, Lyon, published on-line: <http://monographs.iarc.fr/ENG/Monographs/vol100A/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100B, A Review of Human Carcinogens: Biological Agents. IARC, Lyon, published on-line: <http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100C, A Review of Human Carcinogens: Metals, Particles and Fibres. IARC, Lyon, to be published on-line by mid-August 2011
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100D, A Review of Human Carcinogens: Radiation. IARC, Lyon, to be published on-line by mid-September 2011
- IARC/NORA. Identification of research needs to resolve the carcinogenicity of high-priority IARC carcinogens: view and expert opinions of an IARC/NORA expert group meeting, Lyon, France, 30 June-2 July 2009. IARC Technical Publication No 42, ISSN 1012-7348 ; ISBN 978-92-832-2449-5, web only: <http://monographs.iarc.fr/ENG/Publications/techrep42/index.php>
- Ward E, Schulte PA, Straif K, Hopf NB, Caldwell JC, Carreón T, DeMarini DM, Fowler BA, Goldstein BD, Hemminki K, Husgafvel-Pursiainen K, Kuempel E, Lewtas J, Lunn RM, Lynge E, McElvenny DM, Muhle H, Nasu-Nakajima T, Robertson LW, Rothman N, Ruder AM, Schubauer-Berigan MK, Siemiatycki J, Silverman D, Smith MT, Sorahan T, Steenland K, Stevens RG, Vineis P, Zahm SH, Zeise L, Coglianov VJ. Research recommendations for selected IARC-classified agents. *Env. Health Perspect.* 2010; 118: 1355-1362

Program Director/Principal Investigator (Last, first, middle): STRAIF, Kurt

GRANT NUMBER
2U01CA033193-29 REV.

CHECKLIST

1. PROGRAM INCOME (See instructions.)

All applications must indicate whether program income is anticipated during the period(s) for which grant support is requested. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

2. ASSURANCES/CERTIFICATIONS (See instructions.)

In signing the application Face Page, the authorized organizational representative agrees to comply with the policies, assurances and/or certifications listed in the application instructions when applicable. Descriptions of individual assurances/certifications are provided in Part III of the PHS 398, and listed in Part I, 4.1 under Item 14. If unable to certify compliance, where applicable, provide an explanation and place it after the Progress Report (Form Page 5).

3. FACILITIES AND ADMINISTRATIVE (F&A) COSTS

Indicate the applicant organization's most recent F&A cost rate established with the appropriate DHHS Regional Office, or, in the case of for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office.

F&A costs will **not** be paid on construction grants, grants to Federal organizations, grants to individuals, and conference grants. Follow any additional instructions provided for Research Career Awards, Institutional National Research Service Awards, Small Business Innovation Research/Small Business Technology Transfer Grants, foreign grants, and specialized grant applications.

DHHS Agreement dated: 08/11/2010 No Facilities and Administrative Costs Requested.

No DHHS Agreement, but rate established with _____ Date _____

CALCULATION*

Entire proposed budget period: Amount of base \$ 762,415 x Rate applied 16.10 % = F&A costs \$ 122,749

Add to total direct costs from Form Page 2 and enter new total on Face Page, Item 8b.

*Check appropriate box(es):

Salary and wages base Modified total direct cost base Other base (Explain)

Off-site, other special rate, or more than one rate involved (Explain)

Explanation (Attach separate sheet, if necessary.):

Base is total direct costs.

ALL PERSONNEL REPORT

GRANT NUMBER

2U01CA033193-29 REV.

Place this form at the end of the signed original copy of the application. Do not duplicate.

Always list the PD/PI(s). In addition, list all other personnel who participated in the project during the current budget period for at least one person month or more, regardless of the source of compensation (a person month equals approximately 160 hours or 8.3% of annualized effort). Use the following abbreviated categories for describing Role on Project:

- PD/PI
- Co-Investigator
- Faculty Collaborator
- Staff Scientist (doctoral level)
- Postdoc (Postdoctoral Scholar, Fellow, or Other Postdoctoral Position)
- Grad Rsch Asst (Graduate Research Assistant)
- Undergrad Rsch Asst (Undergraduate Research Assistant)
- Rsch Asst (Research Assistant/Coordinator)
- Technician
- Consultant
- Biostatistician
- Other (Specify)

If personnel are supported by a Reentry or Diversity Supplement or American Recovery and Reinvestment Act (ARRA) funding, please indicate such after the Role on Project, using the following abbreviations: RS - Reentry Supplement; DS - Diversity Supplement; AF - General ARRA Supplement; ASE - ARRA Summer Experience funding.

Use Cal (calendar), Acad, or Summer to enter months devoted to project.

Commons ID	Name	Degree(s)	SSN (last 4 digits)	Role on Project	DoB (MM /YY)	Cal	Acad	Summer
k.straif	Straif, Kurt	MD, PhD	N/A	PI from 1 Dec. 10	(b)(6)	(b)(4), (b)(6)		
v.cogliano	Cogliano, Vincent	PhD	N/A	PI until 30 Nov. 10				
	Baan, Robert	PhD	N/A	Co-Investigator				
	Benbrahim-Tallaa, Lamia	PhD	(b)	Staff Scientist				
	Bouvard, Véronique	PhD	N/A	Staff Scientist				
	Egraz, Sandrine	BA	N/A	Other (Archivist)				
	El-Ghissassi, Fatiha	PhD	N/A	Staff Scientist				
	Freeman, Crystal	PhD	(b)	Staff Scientist				
	Galichet, Laurent	MS	N/A	Other (Editor)				
	Grosse, Yann	PhD	N/A	Staff Scientist				
	Guha, Neela	PhD	(b)	Staff Scientist				
	Lauby-Secretan, Béatrice	PhD	N/A	Staff Scientist				
	Lorenzen-Augros, Helen	BA	N/A	Other (Secretary)				
	Russell, Dorothy	BA	N/A	Other (Typist)				

International Agency for Research on Cancer



**World Health
Organization**

150 cours Albert Thomas
69372 Lyon cedex 08, France

Section of IARC Monographs
Tel.: +33 4 72 73 85 07
Fax: +33 4 72 73 83 19
E-mail: imo@iarc.fr
<http://monographs.iarc.fr>

Division of Extramural Activities
Support, OER
National Institutes of Health
6705 Rockledge Drive, Room 2207,
MSC 7987
Bethesda, MD 20817
USA

Special courier: tel. 1-301-594.6584

Ref.: IMO/43/4

28 June 2011

Grant No 2U01CA033193-29 REV.

Dear Sirs,

I enclose our Grant Progress Report for the budget period from 1 September 2010 to 31 August 2011, including the budget request of the next period from 1 September 2011 to 31 August 2012.

No biosketches are included as there are no new staff members working on the project since our last progress report.

I trust the enclosed report is satisfactory and look forward to our continued collaboration.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Kurt Straif'.

Kurt Straif, MD, PhD
Head, IARC Monographs Section

ENCL: As mentioned